To determine the effect of nonadherence to antiretroviral therapy (ART) on virologic failure and mortality in naive individuals starting ART.
Introduction
Once started, antiretroviral therapy (ART) is lifelong with the aims of reducing HIV-related morbidity and mortality [1] [2] [3] . Prevention of nonadherence is of utmost importance for HIV disease management because nonadherence increases the risk of virological failure and thus of HIV transmission [4] [5] [6] [7] . The relationship between nonadherence and progression to AIDS or death has rarely been investigated, and all but one study [6] used only standard statistical models to adjust for confounding [8] [9] [10] . Such standard approaches may produce biased effect estimates because they do not properly adjust for time-dependent confounding, which occurs when confounders, predictors of both exposure and outcome, are also affected by prior exposure. For example, choice of ART drug class may be related both to (expected) adherence and mortality risk, and prior adherence may influence future choice of ART drug class [1, [11] [12] [13] . We estimated the relationship between nonadherence and clinical outcomes among antiretroviral-naive patients starting ART in the Swiss HIV Cohort Study (SHCS), using inverse probability weighting of marginal structural models to adjust for time-dependent confounding.
Methods
All antiretroviral-naive SHCS participants with prospectively collected data, who initiated ART between 1 January, 2003, and 1 January, 2012, and completed at least one SHCS adherence questionnaire (SHCS-AQ) during follow-up were included [4, 14, 15] . Outcomes were viral failure, defined as the first HIV-1 RNA viral load more than 500 copies/ml after either achieving viral suppression (viral load <50 copies/ml) or being on therapy for longer than 24 weeks, and all-cause mortality. We also considered a cutoff for viral failure of viral load more than 50 copies/ml. The SHCS-AQ asks participants how often they missed a dose of ART in the previous 4 weeks (none, once a month, once every 2 weeks, once a week, more than once a week, and every day). These response categories were converted to missing none, one, two, or more than two doses of ART in the last 4 weeks, a more clinically meaningful definition that has been shown to be associated with viral failure and development of resistance mutations [4, 7] . For comparability across regimens with different dosing frequencies, percentage adherence was also calculated and categorized as more than 95%, 90-95%, and 90% or less.
Follow-up started at the date of ART initiation (baseline). The baseline confounders of the relationship between nonadherence and clinical outcomes included in the model are provided in Table 1 . Confounders with time updated information were CD4 þ cell count, viral load (mortality model only), time virally suppressed (viral failure model only), ART class, and dosing frequency. Follow-up continued until the outcome was observed, the individual was lost to follow-up (>12 months since their last visit), or 1 December, 2013, whichever came first. As we are most interested in the total effect of nonadherence, individuals were not censored for intermediate endpoints, such as treatment discontinuation or switching. Follow-up of participants missing any time-dependent confounder at baseline started at the first subsequent visit at which the variable was observed.
Both unweighted and weighted (marginal structural models [MSMs]) pooled logistic regression models were developed for viral failure and mortality. In the MSM models, the analysis is weighted to create a pseudopopulation in which time-dependent confounders (which lie on the causal pathway) at time t-1 no longer predict nonadherence at time t allowing for measurement of the total effect of exposure. Provided that there is no unmeasured confounding, the parameter of the MSM estimates the causal effect of nonadherence on viral failure or mortality (for details see eMethods) [11] . In sensitivity analyses, we explored replacing nonadherence as the exposure with the interaction between dosing frequency and nonadherence (missing no doses, missing one to two doses on a once-daily [q.d.] regimen, missing one to two doses on a twice-daily [b.i.d.] regimen, missing more than two doses on a q.d. regimen, and missing more than two doses on a b.i.d. regimen) [4] .
Results
Of 3247 treatment-naive individuals initiating ART during the study period, 86 (2.6%) never completed the SHCS-AQ, three (0.1%) had HIV-2 virus, and three (0.1%) did not have follow-up information. The final dataset included 3155 individuals with 15 020 personyears of observation followed for a median 4.7 years (interquartile range: 2.9-6.9) and completing a median of nine questionnaires (interquartile range: 5-15). By the end of follow-up, 1155 (36.6%) individuals had reported missing one dose, 414 (13.1%) two doses, 333 (10.6%) more than two doses of ART, 601 (19.0%) 95% or less, and 387 (12.3%) 90% or less adherence on at least one occasion. There were 361 (11.4%) individuals lost to follow-up and 104 died (crude mortality rate ratio 6.57, 95% confidence interval [CI]: 5.42-7.97/1000 personyears). For the outcome of viral failure, an additional 174 individuals were excluded because of the absence of follow-up RNA. Of the eligible 2981 individuals, 220 (7.4%) individuals were lost to follow-up and 480 (16.1%) and 1234 (41.4%) experienced viral failure with a threshold of 500 and 50 copies/ml, respectively.
Patient characteristics are shown in Table 1 . Patients differed in baseline characteristics according to their Impact of adherence to antiretroviral drugs Glass et al. 2197 adherence. Individuals who reported missing at least one dose of ART on at least one occasion were more likely to be women, from the heterosexual or injecting drug use transmission group, and initiated ART in earlier years on a b.i.d. regimen without a tenofovir backbone (Table 1) .
Results from regression models were consistent across all definitions of nonadherence and viral failure. Compared with no missed doses, the adjusted but unweighted estimate of the risk of viral failure for missing one dose of ART was 1.13 (95% CI: 0.78-1.64), missing two doses was 2.27 (95% CI: 1.39-3.73), and missing more than two doses was 5.19 (95% CI: 3.21-8.41) ( 
Discussion
Nonadherence, as assessed by self-report, was found to increase the risk of viral failure and mortality in models adjusting for both time-independent and time-updated variables as well as past adherence. Each additional missed dose was associated with an increase in the risk of viral failure exhibiting a clear dose-response relationship, and missing more than two doses of ART had an approximately five-fold increase in the hazard of viral failure and death. Simplification to q.d. regimens can lead to better adherence but our findings indicate an increased risk of viral failure on q.d. compared with b.i.d. regimens in the presence of nonadherence.
It is difficult to compare our results with previous studies because of different measurement methods and definitions of nonadherence. Our effect estimates are somewhat higher than those reported in earlier studies likely because of proper adjustment for time-dependent confounding (providing the total effect of nonadherence) and less precise because of the lower number of events in our study, particularly deaths [8, 9, 16] .
The present study has several strengths and limitations. Like all observational studies, the effect estimates have a causal interpretation only if there is no unmeasured confounding. The strength of the study was our ability to include many important confounders of the relationship between adherence and clinical outcomes (such as psychosocial factors); however, unmeasured confounders, such as lifestyle and health-seeking behaviors, may bias our estimates. We further strengthened the study by doing extensive sensitivity analyses, which verified the robustness of our estimates and did not change the substantive conclusions from the analysis.
Another limitation of this study is the use of self-reported adherence, which is known to overestimate adherence compared with objective measures [17, 18] . Investigation of nonadherence by physicians during consultations may lead to an overestimate of adherence because of poor recall or fear to disclose undesirable behavior. Despite this potential bias, this simple adherence question had the sensitivity to detect different effects of missing doses on different viral load thresholds. Self-report is the most likely candidate for widespread use in daily clinical practice because of its many advantages over other measurement methods, such as low cost and ease of administration.
The SHCS is a long-standing and well described cohort that collects a variety of information longitudinally in a diverse population, including understudied groups such as heterosexuals, drug users, and women, increasing the generalizability of the results. Regardless, additional validation of these findings in other patient populations and cultural settings is warranted.
Over an average follow-up of 5 years, one out of 10 patients reported having missed more than two doses of ART during the last 4 weeks. Regular investigation of adherence at each clinic visit is therefore crucial and reports of nonadherence should alert physicians to not only provide adherence support but to explore potential underlying reasons for the lack of adherence. This opportunity for early and appropriate intervention could lead to a reduction in drug failure and resistance. The sensitivity of this simple adherence question to predict poor clinical outcomes has wide implications and should be considered for use in resource-limited settings where viral load often cannot be measured.
